Cardiac Dimensions, Inc. is currently enrolling patients in the PRIME
(Percutaneous Repair in Functional Mitral Regurgitation) Registry study, a
prospective, multicenter post-market registry that builds on the clinical
experience from Cardiac Dimensions’ AMADEUS,
TITAN and TITAN II studies of the
CARILLON® Mitral Contour System®. Long-term safety and efficacy will be
evaluated in the PRIME Registry through the assessment of hemodynamics,
functional capacity, heart failure hospitalizations as well as quality of life.
The PRIME Registry study is being undertaken at multiple sites in Europe. United States residents are not eligible for the PRIME Registry study.